Martinelli Ida
Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Department of Internal Medicine and Dermatology, IRCCS Ospedale Maggiore Policlinico, University of Milan, Milan, Italy.
Semin Hematol. 2005 Jan;42(1):49-55. doi: 10.1053/j.seminhematol.2004.09.009.
Since the early 1990s attempts have been made to elucidate whether high concentrations of von Willebrand factor (VWF) and factor VIII (FVIII) in plasma are associated with an increased risk of thrombosis. Several prospective studies on the role of VWF in arterial thrombosis, mainly coronary heart disease, were performed in healthy individuals and patients with previous cardiovascular disease. Although the majority showed an association between high VWF levels and arterial thrombosis, others failed to confirm such findings. A smaller number of studies have evaluated FVIII, mainly for its association with venous thrombosis. Two prospective observations, together with several case-control studies, provided solid evidence of an association between high FVIII levels and a first or recurrent episode of venous thrombosis. On the whole, high levels of VWF and FVIII in plasma confer a moderately high risk of arterial and venous thrombosis, respectively. These findings have no therapeutic implication, but they should be taken into account in the assessment of the individual risk profile.
自20世纪90年代初以来,人们一直在尝试阐明血浆中高浓度的血管性血友病因子(VWF)和凝血因子VIII(FVIII)是否与血栓形成风险增加有关。针对健康个体和既往有心血管疾病的患者,开展了几项关于VWF在动脉血栓形成(主要是冠心病)中作用的前瞻性研究。尽管大多数研究表明高VWF水平与动脉血栓形成之间存在关联,但其他研究未能证实这些发现。较少数量的研究评估了FVIII,主要是评估其与静脉血栓形成的关联。两项前瞻性观察研究以及多项病例对照研究,为高FVIII水平与静脉血栓形成的首发或复发事件之间的关联提供了确凿证据。总体而言,血浆中高水平的VWF和FVIII分别赋予动脉和静脉血栓形成中度较高的风险。这些发现没有治疗意义,但在评估个体风险状况时应予以考虑。